Sanofi halted plans to seek approval of amlitelimab in atopic dermatitis, concluding the OX40-ligand antibody would not deliver meaningful improvement over existing standard of care. The move marks an about-face for a program that had been positioned as a potential successor to dupilumab. The decision follows an ongoing reassessment of Sanofi’s immunology pipeline and comes as analysts and market observers reassess next steps for the company’s development portfolio. The company’s statement frames the rationale around patient benefit versus incumbent therapies. For biotech strategy teams, the key signal is portfolio discipline: even late-stage, high-expectation immunology assets can be paused if comparative value is not convincing enough for registrational intent.